Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions

AIDS. 2004 Sep 24;18(14):1951-3. doi: 10.1097/00002030-200409240-00011.


In HIV-1-infected patients with long-term undetectable viraemia on highly active antiretroviral treatment (HAART), we found that pre-HAART plasma viraemia and the baseline proviral DNA level were significantly associated with the viraemia setpoint during scheduled treatment interruptions. In long-term treated patients, pre-HAART viraemia may not be available, and in these circumstances proviral DNA, measured at the time of scheduled treatment interruption, can help to identify patients likely to reach a low viraemia setpoint after treatment interruption.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiretroviral Therapy, Highly Active
  • Cohort Studies
  • DNA, Viral*
  • HIV Infections / drug therapy
  • HIV Infections / genetics*
  • HIV Infections / virology
  • HIV-1 / genetics*
  • Humans
  • Multivariate Analysis
  • Mutation / genetics
  • RNA, Viral / genetics
  • Viremia / genetics
  • Viremia / virology


  • DNA, Viral
  • RNA, Viral